CD40LG and COVID-19: Of the 21 COVID-19 patients recruited, at least 12 patients had increased circulating levels of at least one aPL (antiannexin V IgM: 19%; anticardiolipin IgM: 14%; antiphosphatidylserine IgM: 14% anticardiolipin IgG: 10%; and antiphosphatidylserine IgG: 10%) [180].